CHEMOMAB THERAPEUTICS LTD.

Analyst Reco. Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Delayed Nasdaq Other stock markets 10:11:31 2024-04-25 am EDT			5-day change	1st Jan Change
0.6799 ^USD	+1.48%		-2.87%	+33.31%

Apr. 10	Transcript : Chemomab Therapeutics Ltd. - Special Call
Mar. 07	Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target	23-10-06	MT
Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target	23-06-07	MT
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating	23-04-18	MT
Oppenheimer Adjusts Chemomab Therapeutics' Price Target to $20 From $30, Maintains Outperform Rating	22-03-10	MT
Aegis Capital Initiates Chemomab Therapeutics at Buy Rating With $30 Price Target	21-12-07	MT
Oppenheimer Adjusts Chemomab Therapeutics PT to $30 From $42, Maintains Outperform Rating	21-11-15	MT
CHEMOMAB THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Chemomab Therapeutics With Overweight Rating, $45 Price Target	21-05-26	MT
CHEMOMAB THERAPEUTICS : Oppenheimer Initiates Coverage on Chemomab Therapeutics With Outperform Rating, $42 Price Target	21-05-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer